NEWS ITEM

The SOBAR  Randomized Clinical Trial is Initiated

March 8, 2019

In conjunction with a world leader in functional food clinical evaluations, INQUIS Clinical Research, Zeno Functional Foods has initiated a clinical trial to put the SOBAR to the test. The trial is designed to rigorously evaluate the effect of the SOBAR on alcohol bioavailability (absorption into the systemic circulation) as compared to eating no food or other conventional foods; the trial has been posted to the US government website clinicaltrials.gov. The design of the trial was based on the results obtained using SOBAR prototype bars in clinical case studies (done for both cocktail and wine consumption). In the case study (tested on one individual, 3x for each condition), the SOBAR was effective at reducing the peak blood alcohol level achieved after drinking 2 x 5oz glasses of wine even if it was eaten along with the wine (food consumed during the first 5 minutes of wine drinking). Compared to control foods with the same caloric content, the SOBAR had a significantly greater effect than the savory snack mix or energy bar tested

THE CLINICAL TRIAL

The trial will be a four-arm controlled and randomized design incorporating 20 healthy subjects (10 women, 10 men) and it has received IRB approval for its start in Toronto, Canada. Each test subject will eat a standardized dinner (provided), fast overnight and then report to the Inquis clinic the next morning. There they will consume either no food or a test food (a savory snack mix or SOBAR (210 calories) or a full meal (635 calories)) and then drink a cocktail over 10 minutes. The cocktail is tailored to each individual's weight and sex, but for an average sized man (70kg) it is equivalent to about 3oz of 80-proof liquor, or a double cocktail equivalent. Each subject will repeat this procedure 4x, at 1 week intervals, to complete the study with each subject having tried the no food and 3 different food conditions. The trial is planned to be completed by July of 2019 with the results being published in a peer reviewed scientific journal and posted to the www.getsobars.com website. This trial is unique in that the SOBAR is the first food to be developed to reduce alcohol bioavailability and rigorously evaluated in human testing.


NEWS ITEM

The SOBAR Randomized Clinical Trial is Initiated

March 8, 2019

In conjunction with a world leader in functional food clinical evaluations, INQUIS Clinical Research, Zeno Functional Foods has initiated a clinical trial to put the SOBAR to the test. The trial is designed to rigorously evaluate the effect of the SOBAR on alcohol bioavailability (absorption into the systemic circulation) as compared to eating no food or other conventional foods; the trial has been posted to the US government website clinicaltrials.gov. The design of the trial was based on the results obtained using SOBAR prototype bars in clinical case studies (done for both cocktail and wine consumption). In the case study (tested on one individual, 3x for each condition), the SOBAR was effective at reducing the peak blood alcohol level achieved after drinking 2 x 5oz glasses of wine even if it was eaten along with the wine (food consumed during the first 5 minutes of wine drinking). Compared to control foods with the same caloric content, the SOBAR had a significantly greater effect than the savory snack mix or energy bar tested.


THE CLINICAL TRIAL

The trial will be a four-arm controlled and randomized design incorporating 20 healthy subjects (10 women, 10 men) and it has received IRB approval for its start in Toronto, Canada. Each test subject will eat a standardized dinner (provided), fast overnight and then report to the Inquis clinic the next morning. There they will consume either no food or a test food (a savory snack mix or SOBAR (210 calories) or a full meal (635 calories)) and then drink a cocktail over 10 minutes. The cocktail is tailored to each individual's weight and sex, but for an average sized man (70kg) it is equivalent to about 3oz of 80-proof liquor, or a double cocktail equivalent. Each subject will repeat this procedure 4x, at 1 week intervals, to complete the study with each subject having tried the no food and 3 different food conditions. The trial is planned to be completed by July of 2019 with the results being published in a peer reviewed scientific journal and posted to the www.getsobars.com website. This trial is unique in that the SOBAR is the first food to be developed to reduce alcohol bioavailability and rigorously evaluated in human testing.